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The Yin and Yang of Cardiac Health*Atta Behfar, MD, PHD, Andre Terzic, MD, PHDSEE PAGES 125 AND 133A pre-eminent risk factor for cardiovasculardisease, aging strongly predicts poor out-come; the largest proportion of deaths occurs
in patients 65 years of age or older (>80%) after
myocardial infarction (1), and the numbers are
growing. By the year 2030, those older than 65 years
of age will represent more than 20% of the total U.S.
population (2). Changing global demographics will
produce a record prevalence of age-related cardiovas-
cular disabilities mandating management strategies
capable of limiting myocardial dysfunction in the
elderly (3).
In this context, stem cell–based regenerative ther-
apies are increasingly evaluated as a potentially
transformative means of enriching standard care (4).
By targeting the root cause of disease, regenerative
modalities aim at structural and functional restora-
tion. Stem cell beneﬁt has, however, not been
observed consistently in the clinical setting, encour-
aging assessment of independent variables that
contribute to heterogeneous outcomes (5). Accord-
ingly, use of regenerative therapies in the elderly
prompts investigation into the effectiveness of stem
cell therapy in senescence. In other words, does the
recipient’s age deﬁne permissiveness for regene-
ration, or can stem cells potentiate organ repair
regardless of age?
Tissue health reﬂects the ability of intrinsic
rejuvenative processes to counteract the impact of
cellular senescence, underscoring a fundamental
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biological impact precipitates accelerated aging at
the organ level (Figure 1). With aging, rejuvenative
capabilities steadily decline as resident pools of
progenitor cells are lost and/or become dysfunctional
due to apoptosis, senescence, or transdifferentiation.
In fact, senescent cell burden disrupts functionality
of neighboring cells, corrupting the organ as a whole
(7). The decline in tissue function is compounded
across an individual’s life span due to progressive
damage to the cell machinery. The preponderance of
senescent cells within aging tissues adds to organ
deterioration by altering the microenvironment,
undermining cell integrity and function (8). Clearing
senescent cells improves tissue function, yet cannot
ensure reversion to the pre-aging state (9,10). To
enable normative restitution, extensive replacement
of senescent with youthful cell populations is likely
required. However, would delivery of stem cells
effectively induce an aging reversal? Or does the
pro-senescent milieu impede beneﬁt of transplanted
cells?In this issue of the Journal, Golpanian et al. (11)
mine data from the TAC-HFT (Transendocardial
Autologous Cells in Ischemic Heart Failure Trial) and
POSEIDON (Percutaneous Stem Cell Injection De-
livery Effects on Neomyogenesis) clinical trials to
determine whether age affects the outcome after
stem cell delivery in patients with heart disease.
Grouping patients by age (older vs. younger than
60 years of age) permitted the investigators to assess
whether the detrimental impact of senescence neu-
tralizes regenerative potency, speciﬁcally of mesen-
chymal stem cells in ischemic cardiomyopathy. The
authors report that aging did not affect the beneﬁts
achieved in global function (reﬂected by 6-min walk
distance and Minnesota Living With Heart Failure
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With aging, endogenous stem cell ﬁtness gradually yields to senescence. The “yin-
and-yang” balance between youth/health and aging/disease becomes unbalanced by stem
cell dysfunction or added disease burden. In an attempt to normalize organ function,
delivery of senescent stem cells may prove insufﬁcient in ensuring beneﬁt. Youthful
reconditioning of unﬁt autologous stem cells or delivery of young stem cells from an
allogeneic source could offer strategies to achieve beneﬁt.
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149Questionnaire) and scar size (11). Even with advanced
age, cell therapy response was preserved, supporting
the prospect of regenerative approaches targeting
older populations.
Furthermore, also in this issue of the Journal,
Hariharan et al. (12) recognize the nucleolar stress
sensor nucleostemin as vital to maintaining cellular
“stemness” and thereby organ homeostasis. Down-
regulated in cardiac progenitors derived from
failing adult hearts compared with fetal controls,
nucleostemin works by stabilizing the expression of
c-myc, a prototypic stemness gene, in resident car-
diac stem cells through Pim-1, a pro-survival serine-
threonine kinase. Dysregulation of nucleostemin
in vivo, achieved in the heterozygous nucleostemin
knockout, provokes exhaustion of endogenous car-
diac stem cells precipitating telomere attrition and a
decline in cardiac function, hallmarks of aging.
Diminished expression of stem cell markers (c-kit,
Nanog, Oct4, and KLF4), along with increased
expression of senescent markers (p53 and p16),
indicate accelerated senescence of resident stem
cells that transition away from a multipotent state.
Conversely, nucleostemin overexpression reduces
senescent traits in support of tissue youth (12). This
work thus underscores a role for resident stem cells
in maintaining cardiac youth/health, providing
insight into pathways that may serve to forecast
regenerative potential.
A stem cell capable of mediating beneﬁt on
myocardial structure and function must both reverse
the disease process and counteract the progeric
microenvironment. Recent reports indicate that only
rarely do individuals with heart disease exhibit pro-
genitors demonstrating clinical regenerative potency,
largely due to a lack of stem cells capable of repair
(13,14). Thus, even though the senescent substratemay
permit regeneration, unﬁt stem cells cannot promote it
(Figure 2). One approach to address this issue is to
preselect for populations of younger allogeneic cells
demonstrating measurable cardioregenerative apti-
tude (15). Alternatively, evidence shows that exposure
to a youthful environment can recondition poorly
reparative cells (16,17). This rejuvenating concept has
been exploited to poise autologous stem cells isolated
from heart failure populations and thereby optimize
cardioreparative efﬁcacy (18,19). Through youth-
ful reprogramming, patient-derived stem cells can
thus be armed to acquire a pro-regenerative capacity
(Figure 2).
Given the permissive aging substrate detected
by Golpanian et al. (11) (Figure 1), stem cells
endowed with an enhanced regenerative function
may accommodate rescue of myocardial functionwithout exposing patients to allogeneic therapies
(20). Moreover, identifying nucleostemin as a
molecular mediator underpinning stem cell health
may provide a novel means of assessing progenitor
vitality and, by extension, regenerative potency in
heart disease (12).
In the context of a substrate that appears to
permit regeneration regardless of age (Figure 1),
the balance between the reparative ﬁtness of stem
cells and the detrimental impact of cellular senes-
cence underscores a “yin-and-yang” phenomenon in
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150cardiac health and disease (Figure 2). Thus, although
stem cells are primarily considered to be therapeutic
in the setting of morbidity, newfound knowledge
suggests a potentially novel role in protection
against aging.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Andre Terzic, Mayo Clinic, 200 First Street SW,
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